



Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended) A method for preventing or treating anxiety disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II):



Formula (I)



Formula (II)

wherein

phenyl, is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and,


R₁, R₂, R₃, R₄, R₅ and R₆ are independently selected from the group consisting of hydrogen and C₁-C₄ alkyl; wherein C₁-C₄ alkyl is optionally substituted with phenyl, [wherein the phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, amino, nitro and cyano].

Claim 2 (original) The method of claim 1 wherein X is chlorine.


Claim 3 (original) The method of claim 1 wherein X is substituted at the ortho position of the phenyl ring.

Claim 4 (original) The method of claim 1 wherein R₁, R₂, R₃, R₄, R₅ and R₆ are selected from hydrogen.

Claim 5 (currently amended) A method for preventing or treating anxiety disorders comprising administering to a subject in need thereof a therapeutically effective amount of an enantiomer selected from the group consisting of Formula (I) and Formula (II) or enantiomeric mixture wherein one enantiomer selected from the group consisting of Formula (I) and Formula (II) predominates:



Formula (I)



Formula (II)

wherein

phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and,

R₁, R₂, R₃, R₄, R₅ and R₆ are independently selected from the group consisting of hydrogen and C₁-C₄ alkyl; wherein C₁-C₄ alkyl is optionally substituted with phenyl, [wherein the phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, amino, nitro and cyano].

Claim 6 (original) The method of claim 5 wherein X is chlorine.


Claim 7 (original) The method of claim 5 wherein X is substituted at the ortho position of the phenyl ring.

Claim 8 (original) The method of claim 5 wherein R₁, R₂, R₃, R₄, R₅ and R₆ are selected from hydrogen.


Claim 9 (original) The method of claim 5 wherein one enantiomer selected from the group consisting of Formula (I) and Formula (II) predominates to the extent of about 90% or greater.

Claim 10 (original) The method of claim 5 wherein one enantiomer selected from the group consisting of Formula (I) and Formula (II) predominates to the extent of about 98% or greater.

Claim 11 (currently amended) The method of claim 5 wherein the enantiomer selected from the group consisting of Formula (I) and Formula (II) is an enantiomer selected from the group consisting of Formula (Ia) and Formula (IIa):



Formula (Ia)



Formula (IIa)

wherein

phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and,

R₁, R₂, R₃, R₄, R₅ and R₆ are independently selected from the group consisting of hydrogen and C₁-C₄ alkyl; wherein C₁-C₄ alkyl is optionally substituted with phenyl, [(wherein the phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, amino, nitro and cyano)].

Claim 12 (original) The method of claim 11 wherein X is chlorine.


Claim 13 (original) The method of claim 11 wherein X is substituted at the ortho position of the phenyl ring.

Claim 14 (original) The method of claim 11 wherein R₁, R₂, R₃, R₄, R₅ and R₆ are selected from hydrogen.


Claim 15 (original) The method of claim 11 wherein one enantiomer selected from the group consisting of Formula (Ia) and Formula (IIa) predominates to the extent of about 90% or greater.

Claim 16 (original) The method of claim 11 wherein one enantiomer selected from the group consisting of Formula (Ia) and Formula (IIa) predominates to the extent of about 98% or greater.

Claim 17 (original) The method of claim 5 wherein the enantiomer selected from the group consisting of Formula (I) and Formula (II) is an enantiomer selected from the group consisting of Formula (Ib) and Formula (IIb):



Formula (Ib)



Formula (IIb)

Claim 18 (original) The method of claim 17 wherein one enantiomer selected from the group consisting of Formula (Ib) and Formula (IIb) predominates to the extent of about 90% or greater.

Claim 19 (original) The method of claim 17 wherein one enantiomer selected from the group consisting of Formula (Ib) and Formula (IIb) predominates to the extent of about 98% or greater.

Claim 20 (currently amended) The method as in claim 1 wherein anxiety disorders are selected from generalized anxiety disorder, panic disorders, impulse control disorders, phobic disorders, posttraumatic stress disorder, dissociative states [(selected from amnesia, somnambulism, dissociative identity disorder [or] and depersonalization)], presurgical anxiety states, postsurgical anxiety states [or] and other medical or psychiatric induced anxiety conditions [(selected from anxiety resulting from traumatic brain injury, chronic pain disorders [or] and other chronic disease conditions.)]

Claim 21 (currently amended) The method of claim 20 wherein anxiety disorders are selected from generalized anxiety disorder, panic disorders, impulse control disorders, phobic disorders [or] and posttraumatic stress disorder.

Claim 22 (original) The method of claim 21 wherein the anxiety disorder is posttraumatic stress disorder.

Claim 23 (currently amended) The method of claim 21 wherein panic disorders are selected from panic disorders with agoraphobia, panic disorders without agoraphobia, anticipatory anxiety, recurrent sleep panic attacks, distressing symptoms [(selected from dyspnea, tachycardia, palpitations, headaches, dizziness, paresthesias, choking, smothering feeling, nausea [or] and bloating) or] and feelings of impending doom; wherein impulse control disorders are selected from obsessive-compulsive disorder, bulimia, episodic dyscontrol, trichotillomania, compulsive gambling and kleptomania; and, wherein phobic disorders are selected from social phobia, global social phobia, specific social phobia, simple phobia, agoraphobia, apiphobia, tropophobia, astraphobia, triskaidekaphobia, blennophobia, thalassophobia, claustrophobia, spheksophobia, cynophobia, sciophobia, decidophobia, eletrophobia, scholionophobia, eremophobia, pyrophobia, gamophobia, pnigerophobia, ophidiophobia, odynophobia, nyctophobia, ochlophobia, musophobia, keraunophobia, katagelophobia, kakorrhaphiophobia, hydrophobia, gynophobia, gatophobia, gephyrophobia, acrophobia [or] and amathophobia.

Claim 24 (original) The method of claim 23 wherein the impulse control disorder is obsessive-compulsive disorder.

Serial No. 10/081,713

Claim 25 (previously presented) The method as in claim 1 wherein the therapeutically effective amount is from about 0.01 mg/Kg/dose to about 100 mg/Kg/dose.